Abstract
Anthracyclines are frequently used in the adjuvant setting for breast cancer treatment since it is considered that anthracycline-based chemotherapy treatment benefits breast cancer patients. Nonetheless, these drugs are associated with severe side effects and predictive factors, for sensitivity to anthracyclines, are warranted in clinical practice. Topoisomerase 2 alpha (TOP2A) is considered to be the molecular target of these drugs. The potential predictive value of TOP2A amplification and overexpression has been extensively studied in breast cancer patients treated with anthracyclines. However, results are not conclusive. In this paper, we review some of the published studies addressing the predictive value of TOP2A as well as the cellular functions of this enzyme and its status in breast cancer tissue.
Similar content being viewed by others
References
Tewey KM, Rowe TC, Yang L et al (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–468
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
Järvinen TA, Kononen J, Pelto-Huikko M, Isola J (1996) Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 148:2073–2082
Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440
Osheroff N, Zechiedrich EL, Gale KC (1991) Catalytic function of DNA topoisomerase II. BioEssays 13:269–275
Earnshaw WC, Halligan B, Cooke CA et al (1985) Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol 100:1706–1715
Uemura T, Ohkura H, Adachi Y et al (1987) DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 50:917–925
Brown PO, Cozzarelli NR (1979) A sign inversion mechanism for enzymatic supercoiling of DNA. Science 206:1081–1083
Liu LF, Liu CC, Alberts BM (1980) Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 19:697–707
Drake FH, Hofmann GA, Bartus HF et al (1989). Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28:8154–8160
Goswami PC, Sheren J, Albee LD et al (2000) Cell cycle in coupled variation topoisomerase IIalpha mRNA is regulated by the 30-untranslated region. Possible role of redoxsensitive protein binding in mRNA accumulation. J Biol Chem 275:38384–38392
Christensen MO, Larsen MK, Barthelmes HU et al (2002) Dynamics of human DNA topoisomerases IIα and II β in living cells. J Cell Biol 157:31–44
Sandri MI, Hochhauser D, Ayton P et al (1996) Differential expression of the topoisomerase IIα and β genes in human breast cancer. Br J Cancer 73:1518–1524
Isaacs RJ, Harris AL, Hickson ID (1996) Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells. J Biol Chem 271:16741–16747
Goswami PC, Roti Roti JL, Hunt CR (1996) The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated M. by mRNA stability and is disrupted by heat shock or ionizing radiation. Mol Cell Biol 16:1500–1508
Wells NJ, Hickson ID (1995) Human topoisomerase II alpha is phosphorylated in a cell-cycle phase-dependent manner by a proline-directed kinase. Eur J Biochem 231:491–497
Carpenter AJ, Porter AC (2004) Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol Biol Cell 15:5700–5711
Errington F, Willmore E, Tilby MJ et al (1999) Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol 56:1309–1316
Turley H, Comley M, Houlbrook S et al (1997) The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 75:1340–1346
McPherson JP, Goldenberg GJ (1998) Induction of apoptosis by deregulated expression of DNA topoisomerase II alpha. Cancer Res 58:4519–4524
Felix CA (1998) Secondary leukemias induced by topoisomerase targeted drugs. Biochim BioPhys Acta 1400:233–255
Wong N, Yeo W, Wong WL et al (2009) TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 124:644–652
Shvero J, Koren R, Shvili I et al (2008) Expression of human DNA Topoisomerase II-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables. Am J Clin Pathol 130:934–939
Bredel M, Pollack IF, Hamilton RL et al (2002) DNA topoisomerase II alpha predicts progression free and overall survival in pediatric malignant non-brainstem gliomas. In J Cancer 99:817–820
Nakopoulou L, Lazaris AC, Kavantzas N (2000) DNA topoisomerase II alpha immunoreactivity as a marker of aggressiveness in invasive breast cancer. Pathobiology 68:137–143
Petit T, Wilt M, Velten M et al (2004) Comparative value of tumor grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:2005–2211
Romero A, Martín M, Cheang MC et al (2011) Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol 178:1453–1460
Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167
Depowski PL, Rosenthal SI, Brien TP et al (2000) Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol 13:542–547
Brase JC, Schmidt M, Fischbach T et al (2010) ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 16:2391–2401
Rody A, Karn T, Ruckhäberle E et al (2009) Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 113:457–466
DeAtley SM, Aksenov MY, Aksenova MV et al (1999) Antioxidants protect against reactive oxygen species associated with doxorubicine-treated cardiomyocytes. Cancer Lett 136:41–46
Sarvazyan N (1996) Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am J Physiol 271:H2079–H2085
Ravid A, Rocker D, Machlenkin A et al (1999) 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59:862–867
Minotti G, Menna P, Salvatorelli E et al (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229
Ross WE, Glaubiger DL, Kohn KW (1978) Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta 519:23–30
Zwelling LA, Michaels S, Erickson LC et al (1981) Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4′-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. Biochemistry 20:6553–6563
Tewey KM, Chen GL, Nelson EM, Liu LF (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:9182–9187
Davies SM, Robson CN, Davies SL, Hickson ID (1988) Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263:17724–17729
Gudkov AV, Zelnick CR, Kazarov AR et al (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A 90:3231–3235
Mo YY, Ameiss KA, Beck WT (1998) Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein. Biotechniques 25:1052–1057
Thor AD, Berry DA, Budman DR et al (1998) ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346–1360
Paik S, Bryant J, Park C et al (1998) ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90:1361–1370
Paik S, Bryant J, Tan-Chiu E et al (2000) ERBB2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991–1998
Pritchard KI, Shepherd LE, O’Malley FP et al (2006) ERBB2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103–2111
Gennari A, Sormani MP, Pronzato P et al (2008) ERBB2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100:14–20
De Laurentiis M, Arpino G, Massarelli E et al (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741–4748
Bartlett JM, Munro A, Cameron DA et al (2008) Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 26:5027–5035
Olsen KE, Knudsen H, Rasmussen BB et al; Danish Breast Cancer Co-operative Group (2004) Amplification of ERBB2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43:35–42
Järvinen TA, Tanner M, Bärlund M et al (1999) Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142–150
Press MF, Sauter G, Buyse M et al (2011) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859–867
Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T et al (2006) Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24:2428–2436
Arriola E, Rodriguez-Pinilla SM, Lambros MB et al (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106:181–189
Knoop AS, Knudsen H, Balslev E et al; Danish Breast Cancer Cooperative Group (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J Clin Oncol 23:7483–7490
O’Malley FP, Chia S, Tu D et al (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644–650
Harris LN, Broadwater G, Abu-Khalaf M et al (2009) Topoisomerase II {alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in ERBB2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol 27:3430–3436
Hannemann J, Kristel P, van Tinteren H et al (2006) Molecular subtypes of breast cancer and amplification of topoisomerase IIa: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 95:1334–1341
Bartlett JM, Munro AF, Dunn JA et al (2010) Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11:266–274
Di Leo A, Isola J, Piette F et al (2008) A metaanalysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracyclines-based adjuvant therapy. Presented at the 31st Annual San Antonio Breast Cancer Symposium, 10–14 December, 2008, San Antonio, TX, abstr 705
Di Leo A, Desmedt C, Bartlett JMS et al (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 12:1134–1142
Järvinen TA, Holli K, Kuukasjärvi T, Isola JJ (1998). Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77:2267–2273
Petit T, Wilt M, Velten M et al (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205–211
Desmedt C, Di Leo A, de Azambuja E et al (2011) Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 29:1578–1586
G Estevez L, Fortes JL, Adrover E et al (2009) Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study. Clin Transl Oncol 11:54–59
Durbecq V, Paesmans M, Cardoso F et al (2004) Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 3:1207–1214
Brase JC, Schmidt M, Fischbach T et al (2010) ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 16:2391–2401
O’Malley FP, Chia S, Tu D et al (2011) Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128:401–409
Fritz P, Cabrera CM, Dippon J et al (2005) cerbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res 7:R374–384
Sparano JA, Goldstein LJ, Childs BH et al (2009) Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 15: 7693–7700
Martin M, Romero A, Cheang MC et al (2011) Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 128:127–136
Prat A, Parker JS, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502
Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685
Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, A., Caldés, T., Díaz-Rubio, E. et al. Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?. Clin Transl Oncol 14, 163–168 (2012). https://doi.org/10.1007/s12094-012-0779-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0779-1